Title: Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable
esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials
Version: 0 Date: 16 Apr 2025
Reviewer:  Masayuki Watanabe
Reviewer's report:
The authors conducted a meta-analysis of randomized controlled trials comparing neoadjuvant
chemotherapy and chemoimmunotherapy for resectable esophageal squamous cell carcinoma.
This subject has received significant attention, and thus, this manuscript will provide useful
clinical information for readers. However, there is a serious problem with this manuscript.
1. There is only one article that investigated survival. Also, the study was a phase II trial with
a relatively small case number and a short follow-up period. Figures 3 and 4 are the results of
this particular trial but not from a meta-analysis. Figures 3 and 4 should be removed from this
manuscript to avoid misleading readers.
2. Also, the description of the survival benefits of immunochemotherapy should be weakened,
as there is no concrete evidence.
Title: Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable
esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials
Version: 0 Date: 16 Apr 2025
Reviewer:  Masayuki Watanabe
Reviewer's report:
The authors conducted a meta-analysis of randomized controlled trials comparing neoadjuvant
chemotherapy and chemoimmunotherapy for resectable esophageal squamous cell carcinoma.
This subject has received significant attention, and thus, this manuscript will provide useful
clinical information for readers. However, there is a serious problem with this manuscript.
1. There is only one article that investigated survival. Also, the study was a phase II trial with
a relatively small case number and a short follow-up period. Figures 3 and 4 are the results of
this particular trial but not from a meta-analysis. Figures 3 and 4 should be removed from this
manuscript to avoid misleading readers.
2. Also, the description of the survival benefits of immunochemotherapy should be weakened,
as there is no concrete evidence.
Please review this paper.
user
Title: Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable
esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials
Version: 0 Date: 16 Apr 2025
Reviewer:  Masayuki Watanabe
Reviewer's report:
The authors conducted a meta-analysis of randomized controlled trials comparing neoadjuvant
chemotherapy and chemoimmunotherapy for resectable esophageal squamous cell carcinoma.
This subject has received significant attention, and thus, this manuscript will provide useful
clinical information for readers. However, there is a serious problem with this manuscript.
1. There is only one article that investigated survival. Also, the study was a phase II trial with
a relatively small case number and a short follow-up period. Figures 3 and 4 are the results of
this particular trial but not from a meta-analysis. Figures 3 and 4 should be removed from this
manuscript to avoid misleading readers.
2. Also, the description of the survival benefits of immunochemotherapy should be weakened,
as there is no concrete evidence.
assistant